Tackling domestic violence: is increasing referral enough?
K Hegarty, P Glasziou - The Lancet, 2011 - thelancet.com
Problems are sometimes divided into simple, complex, or chaotic. 1 Intimate-partner
violence or domestic violence—an important contributor to death, disability, and illness for …
violence or domestic violence—an important contributor to death, disability, and illness for …
Multiple sclerosis—quenching the flames of inflammation
J Chataway, DH Miller - The Lancet, 2011 - thelancet.com
Problems are sometimes divided into simple, complex, or chaotic. 1 Intimate-partner
violence or domestic violence—an important contributor to death, disability, and illness for …
violence or domestic violence—an important contributor to death, disability, and illness for …
Monoclonal antibodies
J Graves, EL Waubant - 2011 - Taylor & Francis
There has been considerable progress in the application of monoclonal antibodies to the
treatment of multiple sclerosis over the past 10 years. In the wake of natalizumab's success …
treatment of multiple sclerosis over the past 10 years. In the wake of natalizumab's success …
Ocrelizumab Succeeds in Phase 2 Trial, Broadening the MS Treatment Landscape
R Robinson - Neurology Today, 2011 - journals.lww.com
The trial enrolled 220 patients, ages 18 to 55 years, with relapsing-remitting disease.
Patients were randomized into one of four arms: placebo, 600 mg ocrelizumab, 2000 mg …
Patients were randomized into one of four arms: placebo, 600 mg ocrelizumab, 2000 mg …
[PDF][PDF] ¿ Quo vadis, neurofarmacología?
AV Galende, EG Ontañón - 2011 - researchgate.net
Kranion: Con excepción de las terapias biológicas, se tiene la impresión de que, desde
hace años, la neurofarmacología ha encallado en un arrecife de coral que le impide …
hace años, la neurofarmacología ha encallado en un arrecife de coral que le impide …
[引用][C] Research and development roundup: November 2011
S Goodrick - Nurse Prescribing, 2011 - magonlinelibrary.com
Kappos L, Li D, Calabresi PA et al.(2011) Ocrelizumab in relapsing-remitting multiple
sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet DOI …
sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet DOI …